Last reviewed · How we verify
BD MDI 40 µg
BD MDI 40 µg is a bronchodilator that works by relaxing the muscles in the airways to improve breathing in people with asthma or COPD.
BD MDI 40 µg is a bronchodilator that works by relaxing the muscles in the airways to improve breathing in people with asthma or COPD. Used for Maintenance treatment of asthma, Maintenance treatment of COPD.
At a glance
| Generic name | BD MDI 40 µg |
|---|---|
| Also known as | PT008 |
| Sponsor | Pearl Therapeutics, Inc. |
| Drug class | Corticosteroid inhaler |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
BD MDI 40 µg contains a medication called fluticasone propionate, which is a corticosteroid that reduces inflammation in the airways. This helps to prevent symptoms such as wheezing, coughing, and shortness of breath. By reducing inflammation, BD MDI 40 µg helps to improve lung function and overall quality of life for people with asthma or COPD.
Approved indications
- Maintenance treatment of asthma
- Maintenance treatment of COPD
Common side effects
- Oral thrush
- Headache
- Cough
Key clinical trials
- A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma (PHASE3)
- Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BD MDI 40 µg CI brief — competitive landscape report
- BD MDI 40 µg updates RSS · CI watch RSS
- Pearl Therapeutics, Inc. portfolio CI